Updates in Heart Failure 2023

Chairs: Gianluigi Savarese, Frieder Braunschweig

Organized by: Translational Medical Academy Foundation
Scientific program developed under the scientific oversight of Karolinska University Hospital

December 11th-12th 2023

DECEMBER 11th 2023 (DAY 1)

Download Program

12.00-13.00

Lunch

13.00-13.05 

  • 13.00-13.05 | Greetings and introduction to the congress
    Savarese G (SE) Braunschweig F (SE)
Session 1: Updates from the Heart Failure Association of the European Society of Cardiology

Chairpersons: Savarese G (SE), Rosano G (UK), Lainscak M (SL)

13.05-14.35

  • 13.05-13.20 | Updates in European Guidelines on Heart failure: what changes and why?
    Metra M (IT)
  • 13.20-13.35 | Patient profiling in HFpEF: a roadmap to the treatment of patients with HFpEF
    Anker S (DE)
  • 13.35-13.50 | Latest HFA/ESC scientific statements
    Chioncel O (RO)
  • 13.50-14.35 | Round Table: Ask the experts
    All

14.35-14-50

Coffee Break
Session 2: Latest updates on SGLT2i – multidisciplinary perspectives

Chairpersons: Braunschweig F (SE),, Solomon S (US), Zieroth S (CA)

14.50-16.20

  • 14.50-15.00 | Updates from the EMPEROR Program and EMPULSE
    Anker S (DE)
  • 15.00-15.10 | Updates from the Dapa-HF and DELIVER Programs
    Solomon S (US)
  • 15.10-15.20 | SGLT2i in kidney disease
    Rossing P (DK)
  • 15.20-15.30 | SGLT2i in type 2 diabetes
    Ferrannini G (SE)
  • 15.30-15.40 | What about the mechanisms?
    Ferrannini E (IT)
  • 15.40-15.50 – What to consider when starting a SGLT2i in a patient with cardiometabolic disease
    Rosano G (UK)
  • 15.50-16.20 | Round Table: Ask the experts
    All

16.20-16.35

Coffee Break
Session 3: Iron deficiency in HF: summing up the current evidence

Chairpersons: Butler J (US), Lainscak M (SL)

16.35-17.35

  • 16.35-16.45 | Why to screen HF patients for iron deficiency? Epidemiology and Pathophysiology
    von Haehling S (DE)
  • 16.45-16.55 | Latest data on ferric carboxymaltose
    Anker S (DE)
  • 16.55-17.05 | Latest data on ferric derisomaltose
    Cleland J (UK)
  • 17.05-17.35 | Round Table: Ask the experts
    All
  • 17.35-17.55 | Keynote lecture: State-of-the-art on GLP1-Ra in heart failure
    Petrie M (UK)
  • 17.55-18.00 | Closure of the day
    Savarese G (SE), Braunschweig F (SE)

December 12th 2023 (day 2)

DECEMBER 12th 2023 (DAY 2)
  • 08.25-08.30 | Greetings
    Savarese G (SE), Braunschweig F (SE)
Session 4: Beyond the 4 pillars of pharmacological treatment in HFrEF

08.30-09.40

Chairpersons: Melin M (SE), Swedberg K (SE)

  • 08.30-08.40 | Ivabradine
    Rosano G (UK)
  • 08.40-08.50 | Vericiguat
    Lund L (SE)
  • 08.50-09:00 | Omecamtiv mecarbil
    Solomon S (US)
  • 09.00-09:10 | What is coming next?
    Filippatos G (GR)
  • 09.10-09:20 | Diuretic therapy: where do we stand?
    Zieroth S (CA)
  • 09.20-09.40 | Round Table: Ask the experts
    All
Session 5: The evolving evidence on potassium binders

09.40-10.40

Chairpersons: Lund L (SE), Lainscak M (SL), Zieroth S (CA)

  • 09.40-09.50 | Why do we need potassium binders?
    Savarese G (SE)
  • 09.50-10.00 | Latest data on patiromer
    Butler J (US)
  • 10.00-10.10 | Latest data on SZC
    Rosano G (UK)
  • 10.10-10.40 | Round Table: Ask the experts
    All

10.40-10.55

Coffee Break
Session 6: Implementation of GDMT: where do we stand?

10.55-11.55

Chairpersons: Bayes-Genis A (ES), Cannata A (UK), Hage C (SE)

  • 10.55-11.05 | Status of GDMT implementation worldwide
    Savarese G (SE)
  • 11.05-11.15 | Strategies to implement use of GDMT in HF
    Bozkurt B (US)
  • 11.15-11.25 | Take home messages from the STRONG-HF trial
    Chioncel O (RO)
  • 11.25-11.55 | Round Table: Ask the experts
    All

11.55-12.55

Lunch
Session 7: The complicated relationship between ischemic heart disease and heart failure

12.55-14.05

Chairpersons: Lindmark K (SE), & Lund L (SE)

  • 12.55-13.05 | The PARADISE-MI trial
    Solomon S (US)
  • 13.05-13.15 | The DAPA-MI
    James S (SE)
  • 13.15-13.25 | The EMPACT-MI
    Butler J (US)
  • 13.25-13.35 | The REVIVED-BCIS2
    Petrie M (UK)
  • 13.35-14.05 | Round Table: Ask the experts
    All
Session 8: Heart Failure Devices

14.05-15.05

Chairpersons: Cleland J (UK), Kinugawa K (JP), Ståhlberg M (SE)

  • 14.05-14.15 | Primary prophylactic ICD in HF: current debates
    Braunschweig F (SE)
  • 14.15-14.25 | Resynchronization by CRT or conduction system pacing
    Linde C (SE)
  • 14.25-14.35 | MONITOR HF
    Brugts J (NL)
  • 14.35-15.15 | Round Table: Still room for devices on top of pharmacological therapies?
    All

15.15-15.30

Coffee Break
Session 9: Treating mitral and tricuspid regurgitation in HF

15.30-16.20

Chairpersons: Braunschweig F (SE), Savarese G (SE), Rück A (SE)

  • 15.30-15.40 | The importance to treat MR and TR in heart failure
    Butler J (US)
  • 15.40-15.50 | Treating MR in the context of HF effectively
    Adamo M (IT)
  • 15.50-16.00 | Treating TR today and tomorrow
    Rück A (SE)
  • 16.00-16.20 | Round Table: Ask the experts
    All
Session 10: The best of HF publications in 2023

16.20-16.50

Chairpersons: Savarese G (SE) & Bayés-Genís A (ES)

  • 16.20-16.30 | European Journal of Heart Failure
    Adamo M (IT)
  • 16.30-16.40 | JACC HF
    Bozkurt B (US)
  • 16.40-16.50 | ESC HF
    Bäck M (SE)
  • 16.50-16.55 | Closure of the day
    Savarese G (SE) & Braunschweig F (SE)
Scroll to Top